The Antibody Drug Conjugate Market is expanding globally as healthcare providers seek effective targeted therapies for oncology. Increasing cancer incidence and the demand for precision medicine are driving investments in ADC R&D. Advanced antibody engineering and cytotoxic payload enhancements are enabling ADCs to overcome traditional chemotherapy limitations, making them increasingly...